X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): DSP107,Atezolizumab
Therapeutic Area: Oncology Product Name: DSP107
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: aMoon
Deal Size: $46.5 million Upfront Cash: Undisclosed
Deal Type: Financing June 16, 2021
Details:
Proceeds will enable further clinical development of DSP107, a first-in-class CD47x41BB targeting fusion protein, for the treatment of solid and hematological tumors and accelerate the path towards clinical development of the Company's preclinical pipeline.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): COM701,Nivolumab,BMS-986207
Therapeutic Area: Oncology Product Name: PVRIG
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2021
Details:
Article highlights include Detailed overview of the DNAM-1 axis including axis checkpoint molecules: DNAM-1, TIGIT, PVRIG and CD96, along with their ligands PVR and PVRL2.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
